A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function - Trial NCT06370819
Access comprehensive clinical trial information for NCT06370819 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 1
Apr 15, 2024
Apr 19, 2025
Primary Outcome
Area under the curve (AUC)0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with normal function, and mild, moderate and severe impairment
Summary
NNC0519-0130 is a new medicine to improve the treatment options for people living with type 2
 diabetes and people with overweight. In this study one dose of NNC0519-0130 will be given and
 blood levels of NNC0519-0130 will be compared between people with reduced kidney function and
 people with normal kidney function. The study will last up to 52 days including a screening
 phase of up to 28 days prior to dosing.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370819
Non-Device Trial